Skip to main content

Table 1 Patient characteristics

From: Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial

 

Treatment group

(n = 15)

Placebo group

(n = 6)

p

Agea

70 (46, 76)

63 (57, 77)

0.97

Sex-ratio

6.5

2

0.54

Baseline APACHE IIa

19 (14, 20)

15 (9, 19)

0.22

Baseline SOFA Scorea

8 (5, 10)

10 (7, 11)

0.56

Source of infection, (n (%))

 - Pulmonary

 - Intra-abdominal

 - Blood stream

 - Skin and soft tissue

 - Endocarditis

 - Urinary tract

5 (24%)

5 (24%)

2 (10%)

2 (10%)

1 (5%)

0

3 (14%)

0

2 (10%)

0

0

1 (5%)

 

Creatinine, (mmol/L)a

115 (78, 224)

155 (80, 553)

0.54

White blood cell, (G/L)a

15 (10, 20)

15 (12, 15)

0.47

Lymphocytes, (G/L) a

0.6 (0.4, 1.0)

0.6 (0.3, 0.9)

0.57

CD4 T cells, (103cells/µL)a

0.326 (0.185, 0.673)

0.637 (0.164, 0.703)

0.52

CD8 T cells, (103cells/µL)a

0.112 (0.50, 0.216)

0.134 (0.28, 0.170)

0.97

mHLA-DR, (mAB/cell)a

4153 (2490, 8010)

7679 (3938, 13,481)

0.38

Neutrophils, (G/L)a

12 (9, 18)

12 (10, 13)

0.57

Monocytes, (G/L)a

0.5 (0.4, 1.0)

0.8 (0.7, 0.8)

0.82

Platelets, (G/L)a

130 (58, 256)

87 (74, 96)

0.40

  1. aValues reported are median (interquartile range)